The MSCI World Health Care ETF now offers a great opportunity. After a bear market triggered by Trump’s tariff threats, followed by months of uncertainty from May to September, the sector suffered a drawdown of more than 20%.
In early October, Pfizer reached an exclusive deal with Trump, agreeing to lower prescription drug prices in the U.S. In return, excessive tariffs will be avoided. This breakthrough has reduced policy risk significantly, and similar agreements are expected with other major U.S. and international pharma companies.
From a performance standpoint, the index is deeply undervalued — it has been the worst YTD performer compared to recent years, showing that investors abandoned the sector, creating a strong value opportunity.
Technically, if the current resistance is broken, a new bull market could begin, with potential to quickly recover last year’s levels, especially as more deals are signed across the sector.
(The ETF’s top 10 holdings are displayed in these images)
GeneZ Finance
🚨📈 OPPORTUNISTIC STRATEGY !
The MSCI World Health Care ETF now offers a great opportunity. After a bear market triggered by Trump’s tariff threats, followed by months of uncertainty from May to September, the sector suffered a drawdown of more than 20%.
In early October, Pfizer reached an exclusive deal with Trump, agreeing to lower prescription drug prices in the U.S. In return, excessive tariffs will be avoided. This breakthrough has reduced policy risk significantly, and similar agreements are expected with other major U.S. and international pharma companies.
From a performance standpoint, the index is deeply undervalued — it has been the worst YTD performer compared to recent years, showing that investors abandoned the sector, creating a strong value opportunity.
Technically, if the current resistance is broken, a new bull market could begin, with potential to quickly recover last year’s levels, especially as more deals are signed across the sector.
(The ETF’s top 10 holdings are displayed in these images)
1 day ago | [YT] | 0
View 0 replies